TCG Crossover Management, LLC

Q2 2025 13F Holdings

  • Location
    palo alto, CA
  • Num holdings

    38

  • Value ($000)

    $875,508

  • Date Filed
    08/14/2025
  • Form type
    13F-HR
  • CIK
    0001839948
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q2 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
CGON
CGON

CG ONCOLOGY INC

COMM
$95.43M
11 %

3,670,206

TNGX
TNGX

TANGO THERAPEUTICS INC

COMM
$54.97M
6 %

10,736,000

COGT
COGT

COGENT BIOSCIENCES INC

COMM
$50.00M
6 %

6,964,375

OCUL
OCUL

OCULAR THERAPEUTIX INC

COMM
$49.36M
6 %

5,319,148

CDTX
CDTX

CIDARA THERAPEUTICS INC

COMM
$49.00M
6 %

1,005,901

---

ABIVAX SA AMERICAN DEPOSITARY SHARES

ADRS
$46.33M
5 %

6,056,596

AMLX
AMLX

AMYLYX PHARMACEUTICALS INC

COMM
$38.10M
4 %

5,943,812

CNTA
CNTA

CENTESSA PHARMACEUTICALS PLC

ADRS
$37.99M
4 %

2,890,816

FULC
FULC

FULCRUM THERAPEUTICS INC

COMM
$36.12M
4 %

5,250,000

DYN
DYN

DYNE THERAPEUTICS INC

COMM
$35.86M
4 %

3,766,660

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 38